form8-k.htm
Form 8-k NOVABAY PHARMACEUTICALS INC.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) November 14, 2008
 
NovaBay Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
 
         
California
  
001-33678
  
68-0454536
(State or other jurisdiction
of incorporation)
  
(Commission
File Number)
  
(IRS Employer
Identification No.)
 
     
5980 Horton Street, Suite 550, Emeryville, CA
  
94608
(Address of principal executive offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code (510) 899-8800
 
Not Applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Item 2.02.
Results of Operations and Financial Condition.
 
On November 14, 2008, NovaBay Pharmaceuticals, Inc. issued a press release announcing its financial results for the quarter ended September  30, 2008. A copy of the press release is attached as Exhibit No. 99.1 to this report.
 
The information contained in this report, including the exhibit attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in any such filing.
 
Item 9.01.
Financial Statements and Exhibits.
 
 
 
(d)
Exhibits.
     
Exhibit No.
  
Description
     
99.1
  
Press Release, dated November 14, 2008, of NovaBay Pharmaceuticals, Inc.
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
             
Dated: November 18, 2008
      
NOVABAY PHARMACEUTICALS, INC.
       
       
By:
  
/S/ THOMAS J. PAULSON
           
Thomas J. Paulson
Chief Financial Officer and Treasurer
 
 
EXHIBIT INDEX
     
Exhibit No.
  
Description
   
99.1
  
Press Release, dated November 14, 2008, of NovaBay Pharmaceuticals, Inc.